-
Drug Discovery & Therapeutics3 weeks agoIambic prices its IPO, seeking to raise up to $160m
AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
-
Capital, M&A & Industry Strategy3 weeks agoMatchpoint scores $150m for I&I drugs, and other financings
Matchpoint has closed a $150m round for its immunology-focused covalent drugs, with KymaThera, Rouge, Sensible Bio, and Arboretum also raising funds.
-
Capital, M&A & Industry Strategy3 weeks agoargenx’s Forte acquisition delivers coeliac trial win
argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
-
Regulatory Intelligence & Drug Approvals3 weeks agoViatris builds in pain relief with $1.65bn Pacira purchase
As it waits for an FDA decision on one non-opioid pain drug, Viatris has its eye on two more, via a takeover bid for Pacira BioSciences.
-
Regulatory Intelligence & Drug Approvals3 weeks agoPfizer’s Tukysa greenlit for earlier use in breast cancer
Pfizer gets FDA approval for maintenance use of its oral HER2 inhibitor Tukysa in breast cancer, which it hopes will unlock renewed sales growth.
-
Global Biotechnology & Pharmaceutical Markets3 weeks agoPhRMA sues Trump administration over GLOBE rebate scheme
PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation pricing in Medicare Part B in a US district court.
-
Capital, M&A & Industry Strategy3 weeks agoBiohub raises $1.8bn for its ‘virtual biology’ initiative
Just months after launching an open-source 'virtual biology' platform, Biohub has raised $1.8 billion in backing for the AI-powered initiative.
-
Regulatory Intelligence & Drug Approvals4 weeks agoClick claims FDA okay for first-in-class schizophrenia DTx
Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia, a DTx called Motivista.
-
Capital, M&A & Industry Strategy4 weeks agoAstraZeneca cuts ribbon on new R&D facility in Massachusetts
AstraZeneca's has opened a new R&D centre in the biotech hotspot of Cambridge, Massachusetts, the centrepiece of a $1bn investment in the state.
-
Clinical Trials & Development4 weeks agoVaxcyte’s pneumococcal jab exceeds expectations
Shares in Vaxcyte have rocketed on phase 3 trial data for its pneumococcal vaccine VAX-31 that suggests it could take on rivals from Pfizer and MSD.
Widespread atropine use fails to sway FDA advisors on Sydnexis data
At least 11 PDUFAs on FDA’s November docket
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
